1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Western Europe Prevalence and Incidence of Peripheral Artery Disease and  Critical Limb Ischemia 2017

Western Europe Prevalence and Incidence of Peripheral Artery Disease and Critical Limb Ischemia 2017

  • May 2017
  • 71 pages
  • ID: 5395309
  • Format: PDF

Summary

Table of Contents

Research on the epidemiology of peripheral artery disease (PAD) and critical limb ischemia (CLI) remains sparse. Since the 2010 publication of Critical Limb Ischemia Volume II Western Europe Epidemiology, almost no country-specific new epidemiological studies have been published. However, a considerable amount of data has been published on the growing prevalence of diabetes.

Over the last seven years, diabetes has increased significantly in Western Europe. This is particularly true in the elderly, the population at highest risk for developing PAD and CLI. According to our estimates, the epidemic of diabetes in the elderly and middle-aged population has caused substantial increases in the prevalence of PAD and CLI in most of the Western European countries

The new 2017 publication contains a comprehensive analysis of the most recently reported prevalence of diabetes in each of the 15 major Western European markets. The 15 countries include: Germany, Italy, Spain, the U.K., France, Greece, the Netherlands, Austria, Switzerland, Belgium, Portugal, Sweden, Finland, Denmark and Norway.

Employing the Diabetes Method, the 2015 prevalence of PAD and CLI are estimated for each country, and the prevalence of each is projected for the 2015-2030 period. These revised prevalence estimates are compared with THE SAGE GROUP’S previous estimates published in 2010. THE SAGE GROUP’S estimates are also compared with PAD and CLI estimates based on available country-specific studies.
The Diabetes Method is an age- and glucose-based method to estimate atherosclerotic lower limb disease. Employing U.S. Census Bureau’s International Data Base (IDB), the population is segmented into 3 age groups. Within each of these age groups, the population is divided into two glucose states: Diabetic (diagnosed and undiagnosed) and Nondiabetic (normal glucose and prediabetes). PAD is calculated according to the percentage prevalence in each glucose state. Then the prevalence of CLI is calculated in those with PAD by glucose status.

PAD and CLI incidence estimates are included for 2015-2030.

Prevalence is defined as the number of new and old cases of PAD and CLI. Incidence is defined as the annual number of new cases of these diseases.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Myocarditis - Pipeline Review, H1 2019

Myocarditis - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Myocarditis - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Pipeline Review, H1 2019, provides an overview of the Myocarditis ...

2019 Myocardial Ischemia Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

2019 Myocardial Ischemia Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

  • $ 2199
  • February 2019

The ongoing clinical trial research report- “2019 Myocardial Ischemia Ongoing Clinical Trials Study” analyzes the current scenario of all active Myocardial Ischemia trials across the world. The report ...

Thromboembolism - Pipeline Review, H1 2019

Thromboembolism - Pipeline Review, H1 2019

  • $ 2000
  • January 2019

Thromboembolism - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H1 2019, provides an overview of ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on